Low ultrafiltration in peritoneal dialysis happens when the membrane lining the abdominal cavity loses its ability to pull enough fluid out of the body during a dialysis exchange. Formally, it is defined as net fluid removal of less than 400 milliliters after a four-hour dwell using a standard high-concentration dextrose solution.1American Journal of Kidney Diseases. What Causes Low Ultrafiltration in Peritoneal Dialysis? The causes are rarely a single problem. Instead, several biological processes converge over time, and understanding each one matters because they call for different interventions.
How Fluid Removal Normally Works Through the Peritoneum
In peritoneal dialysis, a sugar-based solution is infused into the abdominal cavity through a catheter. The high sugar concentration creates an osmotic gradient: water moves from the blood capillaries lining the peritoneum into the dialysis fluid because the fluid is more concentrated than the blood. That drawn-out water carries waste products with it. When the fluid is drained a few hours later, excess water and toxins leave the body.
The movement of water across the peritoneal membrane follows multiple pathways. A widely used biophysical framework describes the membrane as having three types of pores: very small channels that allow only water molecules through, medium-sized pores that let water and small dissolved substances pass, and rare large pores through which proteins can cross. The medium-sized pores account for roughly 90 percent of total water filtration capacity, while the ultra-small water-only channels handle most of the rest.2PubMed. A three-pore model of peritoneal transport When any part of this system is compromised, ultrafiltration drops.
Fast Solute Transport and Rapid Loss of the Osmotic Gradient
The most common cause of low ultrafiltration is a change in how fast the peritoneal membrane moves dissolved substances between blood and dialysis fluid. In people classified as “high transporters,” small molecules like glucose cross the membrane quickly. That sounds efficient, but it creates a problem: the glucose that is supposed to keep the dialysis fluid concentrated gets absorbed into the blood too fast, and the osmotic gradient that drives water removal disappears well before the dwell is complete.3PubMed. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy Once the fluid in the abdomen is no longer more concentrated than the blood, water stops moving in the desired direction. In extreme cases, water can actually flow back into the body.
Some people start peritoneal dialysis already having a naturally fast transport rate. In others, the transport rate accelerates over months or years on treatment. Either way, the practical result is the same: long dwells with standard glucose-based solutions yield disappointing fluid removal, and the patient retains fluid they should be losing.
Aquaporin Dysfunction
The ultra-small water-only channels in the peritoneal membrane are formed by a protein called aquaporin-1. These channels are especially important for the early, rapid phase of water removal during a dwell, because they respond directly to the osmotic pull of glucose. When aquaporin-1 expression or function drops, the membrane loses a significant portion of its water-transport capacity even if the medium-sized pores are working normally.4PubMed. Update on mechanisms of ultrafiltration failure
Research has identified a genetic variant in the promoter region of the aquaporin-1 gene that reduces how much of the protein cells produce. In mechanistic studies, this variant was linked to decreased aquaporin-1 expression and lower glucose-driven water transport across the peritoneum.5PubMed. AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis In children on chronic peritoneal dialysis, the same variant was associated with lower baseline ultrafiltration on standardized testing compared to children without it.6PubMed. Correlation between polymorphisms of the aquaporin-1 gene and peritoneal function in children on chronic peritoneal dialysis Aquaporin loss can also happen as a consequence of chronic membrane injury and fibrosis, meaning it is both a genetic risk factor and a secondary casualty of long-term peritoneal dialysis.
Lymphatic Reabsorption
Not all fluid that enters the abdominal cavity stays there until drain time. The peritoneum has a lymphatic drainage system that continuously reabsorbs fluid from the cavity back into the body. This reabsorption works against the ultrafiltration process. During a dwell, the peak volume of fluid in the abdomen occurs well before glucose has fully equilibrated between blood and dialysate. That peak happens at the moment when the rate of new water entering the cavity drops to match the rate at which lymphatics are pulling it back out. After that crossover point, the lymphatic absorption rate exceeds the rate of new water entry, and the intraperitoneal volume actually decreases.7PubMed Central. Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis
In some patients, lymphatic reabsorption is unusually vigorous. For those individuals, even a good osmotic gradient cannot keep up, because fluid is being siphoned back almost as fast as it arrives. This is a frustrating cause of low ultrafiltration because it is harder to diagnose than fast transport, and there is no reliable way to directly slow lymphatic drainage. The practical impact is that the drained volume at the end of a dwell can be much less than expected, and the loss is not accounted for by osmotic failure alone.
Structural Damage to the Peritoneal Membrane
Long-term exposure to peritoneal dialysis fluid gradually remodels the membrane itself. The changes are cumulative and interrelated, and they represent the most worrying category of ultrafiltration loss because much of the damage is difficult to reverse.
Fibrosis Under the Surface
Beneath the thin layer of cells lining the peritoneum, a zone of fibrous tissue can develop over time. This submesothelial fibrosis acts like insulation, increasing the distance that water and solutes must travel between the blood capillaries and the dialysis fluid. The thicker this fibrotic layer becomes, the more it impairs both water removal and waste clearance.4PubMed. Update on mechanisms of ultrafiltration failure Fibrosis also appears to interfere with aquaporin function, compounding the problem from more than one direction.
New Blood Vessel Growth
Chronic inflammation from dialysis fluid triggers the growth of new blood vessels in the peritoneal membrane, a process driven in large part by vascular endothelial growth factor (VEGF). This protein is found at elevated levels in the drained fluid of long-term peritoneal dialysis patients and is closely associated with changes in peritoneal transport function.8Peritoneal Dialysis International. Vascular endothelial growth factor-mediated peritoneal neoangiogenesis in peritoneal dialysis More blood vessels in the membrane means a larger surface area for glucose absorption, which accelerates the loss of the osmotic gradient described earlier. It is a vicious cycle: glucose-based fluid injures the membrane, the injury spawns new vessels, and the new vessels make glucose-based fluid less effective.
Encapsulating Peritoneal Sclerosis
At the far end of the damage spectrum lies encapsulating peritoneal sclerosis, a rare but severe complication in which the peritoneum becomes so thickened and fibrotic that it forms a rigid cocoon around the intestines. The incidence is estimated at roughly one to three percent of peritoneal dialysis patients and rises with years on therapy.9PubMed Central. Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease At that stage, ultrafiltration has long since failed, and the clinical concern shifts to bowel obstruction. It is the extreme outcome of the same chronic injury that drives the subtler structural changes seen in earlier stages.
The Role of Dialysis Fluid Chemistry
Conventional peritoneal dialysis fluids are acidic, hyperosmotic, and loaded with glucose. During heat sterilization of these solutions, glucose breaks down into byproducts called glucose degradation products (GDPs). These byproducts are directly toxic to the cells lining the peritoneum. Over time, they promote a process in which the flat, tightly packed mesothelial cells that normally coat the membrane transform into more disorganized, mobile cells with a different shape and function. This cellular transition was consistently associated with exposure to high-GDP solutions in a study of peritoneal dialysis patients, outweighing other factors like infection episodes or diabetes.10Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. The Effect of Low Glucose Degradation Product Dialysis Solution on Epithelial-To-Mesenchymal Transition in Continuous Ambulatory Peritoneal Dialysis Patients
The loss of a healthy mesothelial lining leaves the underlying tissue exposed to further injury, accelerating fibrosis and inflammation. GDPs also contribute to the formation of advanced glycation end-products, which cross-link proteins in the tissue and stiffen the membrane. The fluid that is supposed to treat kidney failure is simultaneously, slowly, degrading the organ it depends on to work.
Genetic Variability in Membrane Performance
Not everyone starts peritoneal dialysis on equal footing. Before a single exchange has taken place, there is already wide variation in how fast the membrane transports solutes and how much fluid it can remove. Some of this variation is driven by clinical factors like body size and underlying disease, but genetics play a measurable role as well. A polymorphism in the gene for interleukin-6, a key inflammatory signaling molecule, has been shown to influence baseline small-solute transport rate at the start of peritoneal dialysis, supporting the idea that inflammatory tone is partly hardwired.11PubMed. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane
The aquaporin-1 gene variants mentioned earlier represent a separate genetic influence on water transport specifically. Children carrying two copies of the risk variant for rs2075574 had ultrafiltration volumes on standardized testing that were about a quarter lower than those with two copies of the common variant.6PubMed. Correlation between polymorphisms of the aquaporin-1 gene and peritoneal function in children on chronic peritoneal dialysis These genetic differences help explain why some patients develop ultrafiltration problems early and unpredictably, while others maintain adequate fluid removal for many years.
Strategies That Help Preserve or Restore Ultrafiltration
Because the causes of low ultrafiltration are varied, no single fix works for everyone. Management typically involves a mix of prescriptive changes, fluid reformulations, and sometimes medications aimed at slowing membrane deterioration.
Switching the Osmotic Agent
For patients with fast solute transport, the fundamental problem is that glucose gets absorbed too quickly. One effective workaround is icodextrin, a large glucose polymer that creates its osmotic effect through a different mechanism. Because icodextrin molecules are too big to cross through the small and medium pores rapidly, the osmotic gradient it generates is sustained over much longer dwell times. In studies of long dwells with icodextrin, net ultrafiltration was similar across high, high-average, and low-average transport groups, erasing the disadvantage that fast transporters experience with glucose-based solutions.12PubMed Central. Long Peritoneal Dialysis Dwells With Icodextrin: Kinetics of Transperitoneal Fluid and Polyglucose Transport Icodextrin is typically used for the longest exchange of the day, such as the overnight dwell in continuous ambulatory peritoneal dialysis or the daytime dwell in patients using automated cyclers.
Biocompatible Dialysis Solutions
Newer dialysis fluids are designed with lower glucose degradation product content and a neutral pH, in contrast to the acidic, GDP-heavy conventional solutions. Evidence suggests these formulations slow down the structural changes to the membrane, reducing the severity of fibrosis and the cellular transformation that conventional fluids promote, although they do not prevent all damage entirely.13PubMed. Do low GDP neutral pH solutions prevent or retard peritoneal membrane alterations in long-term peritoneal dialysis? In practice, patients on low-GDP solutions show less mesothelial cell loss and faster healing of the peritoneal lining after injury.10Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. The Effect of Low Glucose Degradation Product Dialysis Solution on Epithelial-To-Mesenchymal Transition in Continuous Ambulatory Peritoneal Dialysis Patients These solutions are widely available in many countries, though cost and regional formulary differences limit universal adoption.
Medications That Protect the Membrane
Angiotensin-converting enzyme (ACE) inhibitors, commonly used to treat high blood pressure, appear to have a protective effect on the peritoneal membrane beyond their cardiovascular role. In peritoneal dialysis patients, ACE inhibitors have been shown to reduce protein leakage across the peritoneum and slow the increase in small-solute transport that typically occurs over time on dialysis.14PubMed Central. The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients The mechanism likely involves dampening the inflammatory and fibrotic pathways that remodel the membrane. Many nephrologists now consider ACE inhibitors or related drugs as part of a strategy to extend the useful life of the peritoneum, particularly in patients already showing signs of rising transport rates.
Prescription Adjustments
When the membrane becomes a fast transporter, shorter and more frequent exchanges can help. The idea is straightforward: by draining and refilling more often, you catch the fluid while the osmotic gradient is still strong, before glucose absorption has flattened it out. Automated peritoneal dialysis machines, which cycle fluid in and out overnight, make this practical. Adding a midday exchange, adjusting fill volumes, or combining glucose-based short dwells with a single long icodextrin dwell are all common tweaks. The specific prescription depends on the patient’s transport characteristics, residual kidney function, and daily fluid intake.
Why Residual Kidney Function Complicates the Picture
Most people beginning peritoneal dialysis still have some remaining kidney function, meaning their own kidneys still contribute a small amount of fluid and waste removal each day. As long as that residual function persists, modest declines in peritoneal ultrafiltration may go clinically unnoticed because the kidneys are picking up the slack. But residual function typically declines over months to years, and when it drops below a critical threshold, the shortfall in peritoneal ultrafiltration suddenly becomes apparent in the form of fluid overload, rising blood pressure, and weight gain. The ultrafiltration problem may have been developing for a long time but was masked.
This is one reason periodic standardized testing of the membrane is recommended. The four-hour test that defines low ultrafiltration gives a snapshot of what the membrane alone can do, independent of what the kidneys contribute. Catching a downward trend early allows for prescription changes before a patient becomes severely fluid-overloaded.
When the Membrane Cannot Be Salvaged
There comes a point for some patients where no combination of solutions, medications, or schedule adjustments can coax adequate fluid removal from the peritoneum. This is sometimes called peritoneal membrane exhaustion. The membrane has accumulated too much fibrosis, too many new vessels, and too little functional mesothelium to sustain effective dialysis. At that point, the standard path is to transition the patient to hemodialysis. Some clinicians advocate for a temporary “peritoneal rest,” a period of weeks to months off peritoneal dialysis during which the membrane may partially recover. Evidence for this approach is mixed, and it requires an alternative dialysis method in the interim.
For patients who develop encapsulating peritoneal sclerosis, the transition off peritoneal dialysis is medically necessary, and surgical intervention may be required to free the bowel from the fibrotic cocoon.9PubMed Central. Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease Fortunately, this outcome remains uncommon and is concentrated among patients with the longest exposure to peritoneal dialysis fluid.
Peritonitis and Its Lasting Effects
Infection of the peritoneal cavity, or peritonitis, is the most feared acute complication of peritoneal dialysis. Beyond the immediate illness, each episode of peritonitis can leave lasting damage to the membrane. Severe or repeated infections accelerate fibrosis, promote new blood vessel growth, and strip away mesothelial cells. The inflammatory response during an infection amplifies many of the same pathways that chronic dialysis fluid exposure activates at a slower pace. A single bad episode can shift a patient’s transport characteristics from average to fast, and a patient who was managing fine before an infection may find their ultrafiltration substantially worse afterward.
Preventing peritonitis through meticulous catheter care and prompt treatment of exit-site infections is therefore not just about avoiding acute illness. It is a membrane preservation strategy. Clinical guidelines emphasize that every averted episode of peritonitis extends the functional lifespan of the peritoneum.
How Multiple Causes Overlap in Real Patients
In practice, low ultrafiltration is almost never caused by just one mechanism. A patient who started with a genetically fast transport rate, accumulated several years of exposure to conventional high-GDP solutions, experienced two episodes of peritonitis, and gradually lost residual kidney function might have contributions from accelerated solute transport, reduced aquaporin function, increased lymphatic reabsorption, and submesothelial fibrosis all at once. Disentangling these contributions is the clinical challenge. Standardized membrane testing can reveal whether the transport rate is high, but it cannot directly measure lymphatic absorption or aquaporin density. Newer research tools exist for those purposes, but they are largely confined to specialized centers and research settings.
The overlapping nature of the problem is why management strategies tend to be layered. A patient with declining ultrafiltration might simultaneously be switched to a biocompatible solution, started on an ACE inhibitor, given icodextrin for the long dwell, and moved to shorter overnight cycles. Each intervention targets a different piece of the puzzle. Whether any single change or the combination is responsible for improvement can be hard to tell, but the practical goal is straightforward: keep enough fluid coming out to keep the patient safe and feeling well for as long as peritoneal dialysis remains viable.